Stay updated on Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Sign up to get notified when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.

Latest updates to the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page
- Check7 days agoChange DetectedThe ClinicalTrials.gov record for the completed dolutegravir study in infants, children, and adolescents is available again, with its study details and supporting materials.SummaryDifference96%

- Check14 days agoChange DetectedThe page remains a 403 Forbidden error rather than showing the clinical study record. The site revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces NIH’s transition update, including the stated shift from using “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 access-denied error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the usual study record content; the top navigation and links to study documents appear unavailable, indicating the record is currently inaccessible.SummaryDifference22%

Stay in the know with updates to Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Immune Response to Dolutegravir in Pediatric HIV Clinical Trial page.